Bryan R Lanning,Landon R Whitby,Melissa M Dix,John Douhan,Adam M Gilbert,Erik C Hett,Theodore O Johnson,Chris Joslyn,John C Kath,Sherry Niessen,Lee R Roberts,Mark E Schnute,Chu Wang,Jonathan J Hulce,Baoxian Wei,Laurence O Whiteley,Matthew M Hayward,Benjamin F Cravatt

Abstract:Kinases are principal components of signal transduction pathways and the focus of intense basic and drug discovery research. Irreversible inhibitors that covalently modify non-catalytic cysteines in kinase active sites have emerged as valuable probes and approved drugs. Many protein classes, however, have functional cysteines, and therefore understanding the proteome-wide selectivity of covalent kinase inhibitors is imperative. Here, we accomplish this objective using activity-based protein profiling coupled with quantitative MS to globally map the targets, both specific and nonspecific, of covalent kinase inhibitors in human cells. Many of the specific off-targets represent nonkinase proteins that, notably, have conserved active site cysteines. We define windows of selectivity for covalent kinase inhibitors and show that, when these windows are exceeded, rampant proteome-wide reactivity and kinase target-independent cell death conjointly occur. Our findings, taken together, provide an experimental road map to illuminate opportunities and surmount challenges for the development of covalent kinase inhibitors.

A Road Map to Evaluate the Proteome-Wide Selectivity of Covalent Kinase Inhibitors.